A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF MTX-463 IN PARTICIPANTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF)
- Registry ID
- MTX-463-I201
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE2
- Study type
- INTERVENTIONAL
- Sponsor
- MEDIAR THERAPEUTICS
- Start date
- 2025-07-07
- Last update
- 2025-05-22
Conditions
- IDIOPATHIC PULMONARY FIBROSIS (IPF)
Related clinical trials
- A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 CLINICAL TRIAL OF THE EFFICACY AND SAFETY OF MNKD-201 (NINTEDANIB DRY POWDER INHALATION) IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS FOLLOWED BY AN OPEN-LABEL EXTENSION
- IDIOPATHIC PULMONARY FIBROSIS: A PHASE 2A PLATFORM STUDY OF INVESTIGATIONAL PRODUCTS FOR THE TREATMENT OF ADULT SUBJECTS
- A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL PIPE-791 IN SUBJECTS WITH IDIOPATHIC PULMONARY FIBROSIS
- A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 PROOF OF CONCEPT (POC) STUDY EVALUATING THE SAFETY, TOLERABILITY, AND EFFICACY OF NINTEDANIB SOLUTION FOR INHALATION (AP02) IN PARTICIPANTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF) (AURA-IPF)
- A MULTINATIONAL, LONG-TERM, OPEN-LABEL EXTENSION STUDY OF SUBJECTS WHO HAVE PARTICIPATED IN AVALYN PHARMA STUDIES OF INHALED ANTIFIBROTIC AGENTS (AP-LTE-008 [SAIL])
- A DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED, PARALLEL GROUP, PHASE IIA TRIAL TO
EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY OF
BI 765423 ADMINISTERED INTRAVENOUSLY WITH OR WITHOUT STANDARD OF CARE IN PATIENTS
WITH IDIOPATHIC PULMONARY FIBROSIS
View on source registry